This article was originally published in The Gray Sheet
Executive SummaryPremarket approval application for the firm's KeraVision reversible vision correction implant ring, filed by FDA in August, is slated to be reviewed by the agency's Ophthalmic Devices Panel at a Jan. 12 meeting, the firm reports. The Fremont, California company expects to debut the device in 1999 with a moderate myopia indication ("The Gray Sheet" Nov. 16, p. 25)
You may also be interested in...
India’s Sun Pharma has been denied leave to appeal against a US court decision rejecting the company’s bid for dismissal of a multi-district antitrust lawsuit.
Former Sandoz executive Hector Armando Kellum has admitted involvement in a US generic price-fixing conspiracy, the US Department of Justice has announced.
The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.